Risk of haematopoietic cancer in patients with inflammatory bowel disease

Askling, J; Brandt, L; Lapidus, A; Karlén, P; Björkholm, M; Löfberg, R; Ekbom, A
May 2005
Gut;May2005, Vol. 54 Issue 5, p617
Academic Journal
Background and aims: Several chronic inflammatory conditions are associated with an increased risk of lymphoma. Whether this applies to inflammatory bowel disease (IBD) is still unclear but of paramount interest, particularly in the safety evaluation of newer immunosuppressive drugs. Reports also indicate a possible increase in the risk of leukaemia in IBD. We therefore assessed the risk of haematopoietic cancers in a large cohort of patients with IBD. Subjects and methods: We performed a population based cohort study using prospectively recorded data, including 47 679 Swedish patients with Crohn's disease (CD) or ulcerative colitk (UC) assembled from regional cohorts of IBD from 1955 to 1990 (n = 8028) and from the Inpatient Register of 1964-2000 (n =45 060), with follow up until 2001. Relative risks were expressed as standardised incidence ratios (SiR). Results: Overall, we observed 264 haematopoietic cancers during follow up, which corresponded to a borderline significant 20% increased risk in both UC and CD. in UC, lymphomas occurred as expected (SIR 1.0, n = 87) but myeloid leukaemia occurred significantly more often than expected (SIR 1.8, n = 32). In CD, there was a borderline significant increased lymphoma risk (SIR 1.3, n = 65), essentially confined to the first years of follow up. Proxy markers of disease activity had little impact on lymphoma risk. Conclusion: On average, patients with IBD have a marginally increased risk of haematopoietic cancer. In UC, this is accounted for by an excess of myeloid Ieukaemia. In CD, a modest short term increase in the risk of lymphoma of unknown significance cannot be excluded but any long term risk increase seems unlikely.


Related Articles

  • Clinical epidemiology -- how important now? Binder, V // Gut;May2005, Vol. 54 Issue 5, p574 

    The article focuses on the putative risk of haematopoietic cancer in relation to modern strong immunosuppressive treatment in inflammatory bowel disease. The natural history of a chronic disease should ideally be the background for any therapeutic trial. Modern information technology has...

  • No increased cancer risk with immunosuppressants in IBD.  // Reactions Weekly;2/10/2007, Issue 1138, p4 

    The article discusses research being done on the risk of developing cancer in patients with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, who received immunosuppressants. It references a study by Masunaga et al in the January 2007 issue of "Annals of...

  • Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study. Jess, Tine; Horváth-Puhó, Erzsébet; Fallingborg, Jan; Rasmussen, Henrik H; Jacobsen, Bent A // American Journal of Gastroenterology;Dec2013, Vol. 108 Issue 12, p1869 

    OBJECTIVES:Population-based studies of site-specific cancer risk in patients with inflammatory bowel disease (IBD) according to IBD phenotype and treatment are lacking. We studied cancer risk in a well-characterized population-based IBD cohort from North Jutland County, Denmark.METHODS:A total...

  • Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978—2003. Erichsen, Rune; Jepsen, Peter; Vilstrup, Hendrik; Ekbom, Anders; Sørensen, Henrik // European Journal of Epidemiology;Sep2009, Vol. 24 Issue 9, p513 

    Patients with inflammatory bowel disease (IBD) are at increased risk of cholangiocarcinoma (CC), but quantitative data are scant. Furthermore, little is known about the impact of IBD on CC occurrence and prognosis. Based on nationwide population-based registries we compared the incidence and...

  • Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010/Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Herrinton, L. J.; Liu, L.; Levin, T. R.; Jess, T.; Simonsen, J.; Jørgensen, K. T. // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 1, p19 

    Two studies examining the incidence of and mortality associated with colorectal adenocarcinoma (CRC) in IBD patients have recently been published in Gastroenterology. This is an important and often controversial topic in IBD, and these two studies are of particular interest as they appear to...

  • Risk of Lymphoma in Inflammatory Bowel Disease. Loftus Jr., Edward V.; Tremaine, William J.; Habermann, Thomas M.; Harmsen, W. Scott; Zinsmeister, Alan R.; Sandbom, William J. // American Journal of Gastroenterology;Sep2000, Vol. 95 Issue 9, p2308 

    OBJECTIVE: Inflammatory bowel disease with a subsequent diagnosis of non-Hodgkin's lymphoma has been reported. There is concern that the risk of developing lymphoma will rise with increasing use of immune modifier therapy. We determined the risk of non-Hodgkin's lymphoma in an U.S....

  • IBD patients face increased skin cancer risk.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p35 

    The article reports on the findings of two studies on the increased skin cancer risk in patients with inflammatory bowel disease (IBD). It notes that the study led by Laurent Peyrin-Biroulet has found the risk of nonmelanoma skin cancer (NMSC) in patients with IBD, which is intensified by the...

  • Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Beiggi, S; Johnston, J B; Seftel, M D; Pitz, M W; Kumar, R; Banerji, V; J Griffith, E; Gibson, S B // British Journal of Cancer;9/3/2013, Vol. 109 Issue 5, p1287 

    Background:Chronic lymphocytic leukaemia (CLL) patients have an increased risk of other malignancies. This may be due to surveillance bias, treatment or immunosuppression.Methods:Cohort study of 612 consecutively diagnosed CLL patients in a Canadian province, with comparisons to follicular...

  • Pediatric-onset inflammatory bowel disease increased cancer risk, not mortality.  // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p39 

    The article presents the results of a study as of late October 2013, which showed that the pediatric-onset inflammatory bowel disease (IBD) increased cancer risk by threefold compared with the general population but had no impact on risk for death.


Read the Article


Sign out of this library

Other Topics